drugset / Trial / NCT05980026

Omega-3 Fatty Acids Supplementation Improves Early-stage Diabetic Nephropathy and Subclinical Atherosclerosis in Pediatric Patients With Type 1 Diabetes

NCT05980026

Completed 70 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators conducted this randomized-controlled trial to assess the effect of oral omega-3 supplementation on glycemic control, lipid profile, albuminuria level, kidney injury molecule-1 (KIM-1) and carotid intima media thickness (CIMT) to participants who were pediatric patients with T1DM and diabetic nephropathy.

Timeline

Start
2022-01-10
Primary completion
2022-12-17
Completion
2023-01-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omega-3 fatty acids Unknown 1 g Oral